MB49 Xenograft Model Service for Bladder Cancer

The MB49 Xenograft Model Service for Bladder Cancer provides a robust, immunocompetent preclinical platform for evaluating novel therapeutics against urothelial carcinoma. Alfa Cytology delivers end-to-end model construction, in-life monitoring, and downstream analytical support to accelerate your bladder cancer drug development pipeline with reproducible, publication-ready data.

Overview of MB49 Xenograft Model for Bladder Cancer

The MB49 cell line is a murine urothelial carcinoma line originally derived from C57BL/6 mouse bladder epithelial cells following 24-hour exposure to 7,12-dimethylbenz[a]anthracene (DMBA) and subsequent long-term culture. As a syngeneic model, MB49 tumors are established in immunocompetent C57BL/6 hosts, preserving intact tumor-immune interactions that are critical for evaluating immunotherapies, checkpoint inhibitors, and combination regimens. The model exhibits hormone-responsive growth dynamics, with more rapid tumor progression observed in male mice due to androgen receptor signaling, partially recapitulating the male predominance seen in human bladder cancer epidemiology.

MB49 xenografts can be established via subcutaneous (heterotopic) or intravesical (orthotopic) implantation, offering flexibility for different study objectives. Subcutaneous models enable straightforward tumor volume monitoring and are widely used for efficacy screening, while orthotopic implantation more closely mimics the natural tumor microenvironment of the bladder. The model has been extensively validated for BCG immunotherapy, photothermal therapy combined with immune checkpoint blockade, antibody-drug conjugates, and radiation studies, making it one of the most versatile preclinical platforms for bladder cancer research.

Figure 1. Phase contrast microscopy of MB49 and MB49-I cells. (Mencucci, Maria V, et al., 2020)

Cell Line Information: MB49

The following table summarizes the key characteristics and specifications of the MB49 murine bladder cancer cell line:

Our Services

Alfa Cytology provides comprehensive MB49 xenograft model services spanning from cell line authentication and expansion to in vivo implantation, tumor monitoring, treatment administration, and endpoint histopathological analysis. Our experienced in vivo team ensures consistent model performance, rigorous quality control, and flexible study designs tailored to your specific therapeutic modality---whether small molecules, biologics, cell therapies, or combination regimens.

Workflow of MB49 Xenograft Model Construction

Establishment of the MB49 syngeneic bladder cancer model follows a standardized, quality-controlled workflow designed to ensure reproducible tumor growth and reliable therapeutic readouts. Each phase incorporates stringent health monitoring, randomized group allocation, and blinded tumor measurements to maintain data integrity throughout the study duration.

1. Cell Line Preparation and Quality Control --- MB49 cells are recovered from cryopreserved stocks and expanded under standardized culture conditions. Cell viability is confirmed by Trypan blue exclusion (>=95% viability required), and mycoplasma testing is performed to ensure culture purity. Cells are harvested during logarithmic growth phase using trypsinization, washed, and resuspended in sterile PBS at the designated concentration for implantation.
2. Animal Preparation and Acclimation --- C57BL/6 mice (typically 4--8 weeks old, either sex depending on study objectives) are acquired from accredited vendors and acclimated for 5--7 days. Baseline body weights are recorded, and animals are randomized into treatment groups using stratified randomization based on body weight to minimize inter-group variability.
3. Tumor Cell Implantation --- For subcutaneous models, MB49 cells (5x10^5--1x10^6 in 100 uL PBS, optionally mixed with Matrigel) are injected into the right flank using aseptic technique. For orthotopic models, cells (1x10^5 in 50 uL PBS) are instilled intravesically following transient chemical cauterization of the bladder urothelium to enhance tumor engraftment. Injection sites are monitored daily for the first 72 hours for signs of leakage, infection, or distress.
4. Tumor Monitoring and Randomization --- Tumor development is monitored by palpation every 2--3 days beginning on day 5--7 post-implantation. Once tumors reach the target enrollment volume (typically 60--100 mm^3 for efficacy studies, or ~30 mm^3 for intratumoral treatment initiation), mice are randomized into vehicle control and treatment arms. Tumor dimensions are measured with electronic calipers, and volume is calculated using the ellipsoidal formula: V = (length x width^2) x pi/6.
5. Treatment Administration --- Test compounds, biologics, or combination therapies are administered according to the study protocol---via intraperitoneal, intravenous, intratumoral, or intravesical routes as appropriate. Dosing schedules are strictly adhered to, and all administrations are documented with batch numbers, actual dose volumes, and any observations. Body weights and clinical signs are recorded at least twice weekly to assess treatment tolerability.
6. Endpoint Assessment and Tissue Collection --- Studies are terminated upon reaching predetermined endpoints (e.g., tumor volume of 2,000 mm^3, study day limit, or significant morbidity). At necropsy, tumors are excised, weighed, and dimensions recorded. Tissues are preserved in 10% neutral buffered formalin for histopathology or snap-frozen in liquid nitrogen for molecular analyses. Optional endpoints include flow cytometry of tumor-infiltrating lymphocytes, immunohistochemistry for immune markers, and serum cytokine profiling.

Figure 2. MB49 xenograft model construction workflow.

Case Study-MB49 Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology established subcutaneous MB49 tumors in male C57BL/6 mice to evaluate a novel therapeutic candidate targeting the bladder cancer immune microenvironment. Tumors were successfully engrafted in 100% of implanted animals, with palpable masses appearing within 7--9 days and reaching target volumes by day 14. Treatment arms demonstrated dose-dependent tumor growth inhibition compared to vehicle controls, with acceptable tolerability profiles. Comprehensive endpoint analyses---including tumor weight, immunohistochemical staining for CD8+ T cell infiltration, and serum cytokine panels---provided mechanistic insights into compound activity. Detailed datasets and customized reporting are available upon formal inquiry under confidentiality agreements.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational flexibility to deliver high-quality MB49 xenograft data that supports critical preclinical decision-making. Our integrated service model eliminates vendor coordination overhead while ensuring seamless continuity from study design to final report.

• Proven expertise in syngeneic and orthotopic bladder cancer models with over multiple successfully completed MB49 studies.
• Fully immunocompetent C57BL/6 host platform enabling robust evaluation of immunotherapies, checkpoint inhibitors, and combination strategies.
• Customizable study designs including multiple implantation routes, treatment schedules, and complex combination arms tailored to your compound class.
• Comprehensive analytical capabilities spanning tumor growth kinetics, body weight monitoring, histopathology, IHC/IF, flow cytometry, and cytokine profiling.
• GLP-compliant data collection, audited facilities, and dedicated study directors ensuring regulatory-ready documentation for IND-enabling packages.
• Rapid study initiation with established MB49 cell bank, validated SOPs, and dedicated vivarium capacity to meet aggressive program timelines.

Contact Us

Accelerate your bladder cancer preclinical program with Alfa Cytology's MB49 Xenograft Model Service. Whether you require a standard efficacy study or a complex combination immunotherapy evaluation, our team is ready to design and execute a study that meets your exact specifications. Please reach out to us today via our inquiry form or email to learn more about our MB49 Xenograft Model services.

For research use only. Not intended for any clinical use.